NASDAQ:IMRX Immuneering (IMRX) Stock Price, News & Analysis $2.50 +0.07 (+2.66%) As of 09:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Immuneering Stock (NASDAQ:IMRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Immuneering alerts:Sign Up Key Stats Today's Range$2.54▼$2.5450-Day Range$1.11▼$2.7752-Week Range$1.00▼$3.83Volume39,412 shsAverage Volume2.51 million shsMarket Capitalization$90.15 millionP/E RatioN/ADividend YieldN/APrice Target$13.25Consensus RatingModerate Buy Company OverviewImmuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Read More… Immuneering Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreIMRX MarketRank™: Immuneering scored higher than 70% of companies evaluated by MarketBeat, and ranked 312th out of 921 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingImmuneering has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageImmuneering has only been the subject of 4 research reports in the past 90 days.Read more about Immuneering's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Immuneering are expected to grow in the coming year, from ($1.86) to ($1.52) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immuneering is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immuneering is -1.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuneering has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Immuneering's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.56% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Immuneering has recently increased by 39.92%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmuneering does not currently pay a dividend.Dividend GrowthImmuneering does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.56% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Immuneering has recently increased by 39.92%, indicating that investor sentiment is decreasing significantly. News and Social Media3.8 / 5News Sentiment0.81 News SentimentImmuneering has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Immuneering this week, compared to 2 articles on an average week.Search Interest3 people have searched for IMRX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows4 people have added Immuneering to their MarketBeat watchlist in the last 30 days. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Immuneering insiders have bought more of their company's stock than they have sold. Specifically, they have bought $202,912.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders22.90% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immuneering's insider trading history. Receive IMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter. Email Address IMRX Stock News HeadlinesImmuneering Corporation (NASDAQ:IMRX) CEO Benjamin J. Zeskind Acquires 21,000 SharesJune 21 at 6:48 AM | insidertrades.comInsider Buying: Immuneering Corporation (NASDAQ:IMRX) Director Acquires 40,485 Shares of StockJune 19, 2025 | insidertrades.comHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% worldwide. Now he’s applying the same expertise to the Bitcoin market. His system tracks 19 indicators to find quick Bitcoin profit opportunities.June 24, 2025 | Brownstone Research (Ad)We're A Little Worried About Immuneering's (NASDAQ:IMRX) Cash Burn RateJune 20, 2025 | finance.yahoo.comImmuneering (NASDAQ:IMRX) Given "Buy" Rating at Needham & Company LLCJune 20, 2025 | americanbankingnews.comImmuneering (NASDAQ:IMRX) Price Target Raised to $10.00 at MizuhoJune 20, 2025 | americanbankingnews.comPre-Market Most Active for Jun 17, 2025 : IMRX, TSLL, VERV, RUN, SQQQ, TQQQ, KO, CRCL, DIS, QBTS, BBAI, NIOJune 19, 2025 | nasdaq.comChardan Capital Reaffirms Buy Rating for Immuneering (NASDAQ:IMRX)June 19, 2025 | americanbankingnews.comSee More Headlines IMRX Stock Analysis - Frequently Asked Questions How have IMRX shares performed this year? Immuneering's stock was trading at $2.20 at the beginning of 2025. Since then, IMRX shares have increased by 10.9% and is now trading at $2.44. View the best growth stocks for 2025 here. How were Immuneering's earnings last quarter? Immuneering Corporation (NASDAQ:IMRX) issued its quarterly earnings data on Monday, May, 5th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $0.01. When did Immuneering IPO? Immuneering (IMRX) raised $105 million in an initial public offering (IPO) on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities acted as the underwriters for the IPO. Who are Immuneering's major shareholders? Top institutional shareholders of Immuneering include HighTower Advisors LLC (0.23%), TD Asset Management Inc (0.20%) and Jane Street Group LLC (0.06%). Insiders that own company stock include Benjamin J Zeskind, Peter Feinberg, Leah R Neufeld, Mallory Morales and Harold Eugene Brakewood. View institutional ownership trends. How do I buy shares of Immuneering? Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immuneering own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immuneering investors own include Tesla (TSLA), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Advanced Micro Devices (AMD), Meta Platforms (META) and Home Depot (HD). Company Calendar Last Earnings5/05/2025Today6/24/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMRX CIK1790340 Webwww.immuneering.com Phone617-500-8080FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$13.25 High Stock Price Target$21.00 Low Stock Price Target$9.00 Potential Upside/Downside+443.0%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($1.96) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$61.04 million Net MarginsN/A Pretax MarginN/A Return on Equity-119.22% Return on Assets-99.22% Debt Debt-to-Equity RatioN/A Current Ratio7.48 Quick Ratio7.48 Sales & Book Value Annual Sales$320 thousand Price / Sales274.42 Cash FlowN/A Price / Cash FlowN/A Book Value$1.33 per share Price / Book1.83Miscellaneous Outstanding Shares35,990,000Free Float27,745,000Market Cap$87.82 million OptionableNot Optionable BetaN/A Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:IMRX) was last updated on 6/24/2025 by MarketBeat.com Staff From Our Partners12 “perfect” stocksJoin the Dream Team and see how we can guarantee stock market wins Credentials are a good thing, especiall...Zacks | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredIs Tesla a buy right now?Wall Street Legend: Why stocks are very likely to crash in Trump's 2nd Year Legendary investor Marc Chaikin...Chaikin Analytics | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWall Street is using Bitcoin against youBitcoin is rising again, and institutions are pouring billions into Bitcoin ETFs. At first glance, that mig...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.